Holen Sie sich die Stockscreener-App
0.121
3.20%
-0.004
Schlusskurs vom Vortag:
$0.125
Offen:
$0.133
24-Stunden-Volumen:
297.74K
Relative Volume:
0.31
Marktkapitalisierung:
$8.32M
Einnahmen:
$202.00K
Nettoeinkommen (Verlust:
$-28.96M
KGV:
-0.2017
EPS:
-0.6
Netto-Cashflow:
$-21.85M
1W Leistung:
-6.71%
1M Leistung:
-10.37%
6M Leistung:
-50.61%
1J Leistung:
-73.11%
1-Tages-Spanne:
$0.121
$0.133
1-Wochen-Bereich:
$0.12
$0.1347
52-Wochen-Spanne:
$0.1105
$0.62
AIM ImmunoTech Inc Stock (AIM) Company Profile
Firmenname
AIM ImmunoTech Inc
Sektor
Branche
Telefon
352 448 7797
Adresse
2117 SW Highway 484, Ocala, FL
Vergleichen Sie AIM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AIM
AIM ImmunoTech Inc
|
0.121 | 8.32M | 202.00K | -28.96M | -21.85M | -0.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
AIM ImmunoTech Inc Aktie (AIM) Neueste Nachrichten
AIM ImmunoTech’s Earnings Call: Progress Amid Challenges - TipRanks
AIM ImmunoTech Inc (AIM) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... - Yahoo
AIM ImmunoTech Announces Further Efforts to Establish Clinical Trials Assessing Ampligen as a Potential Protective and Early-Onset Treatment for the Current COVID-19 Pandemic - ACCESS Newswire
AIM Immunotech Inc Files For Mixed Shelf Offering Of Up To $100 MillionSEC Filing - MarketScreener
Why Xos Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket - Benzinga
Earnings Scheduled For March 28, 2025AIM ImmunoTech (AMEX:AIM), China Automotive Systems (NASDAQ:CAAS) - Benzinga
AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Earnings Preview For AIM ImmunoTech - Benzinga
AIM ImmunoTech Inc. (AIM) reports earnings - Quartz
AIM Immunotech Reports Fourth Quarter And Full Year 2024 Financial Results And Provides Corporate Update - Marketscreener.com
AIM ImmunoTech Slashes Expenses While Progressing Cancer Trials With AstraZeneca - Stock Titan
AIM ImmunoTech (AIM) Upgraded to Strong Buy: What Does It Mean for the Stock? - MSN
Critical Comparison: AIM ImmunoTech (NYSE:AIM) & Windtree Therapeutics (NASDAQ:WINT) - Defense World
AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - GlobeNewswire
AIM ImmunoTech Inc. Shares Key Updates on Clinical Trials and Future Plans at Virtual Investor Conference - Nasdaq
AIM ImmunoTech's 5 Game-Changing Programs: Pancreatic Cancer Trial Leads 2025 Strategy - StockTitan
Aim Immunotech CEO Thomas Equels buys $6,730 in stock By Investing.com - Investing.com Canada
Aim Immunotech CEO Thomas Equels buys $6,730 in stock - Investing.com India
What is AIM ImmunoTech Inc (AIM) Stock Return on Shareholders’ Capital? - SETE News
Aim Immunotech CEO Thomas K Equels buys $5,060 in common stock - Investing.com India
Aim Immunotech CEO Thomas K Equels purchases $10,000 in stock By Investing.com - Investing.com Australia
Aim Immunotech CEO Thomas K Equels purchases $10,000 in stock - Investing.com India
AIM ImmunoTech, PepGen, Aeon, Tiziana, Moleculin: 5 Biotech Stocks That Led Retail Message Growth Last Week - Asianet Newsable
AIM ImmunoTech appoints Chemerow as an Independent Director - MSN
AIM ImmunoTech Inc. Appoints Principal Investigator for Clinical Study Combining Ampligen and AstraZeneca's FluMist for Influenza Vaccine Development - Nasdaq
AIM announces Paul Goepfert, MD, as the principal - GlobeNewswire
Could This $10M Avian Flu Vaccine Strategy Outperform Billion-Dollar mRNA Alternatives? - StockTitan
AIM ImmunoTech Inc. to Present at the Fall Investor Summit on September 16th-17th in New York City - ACCESS Newswire
AIM ImmunoTech to Present at the Investor Summit in Philadelphia - ACCESS Newswire
AIM ImmunoTech Inc. Announces its Name Change is Complete, Its New Website is Up and the Company Now Trades as Ticker Symbol 'AIM' - ACCESS Newswire
AIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance - The Manila Times
AIM ImmunoTech Plans to Meet NYSE Compliance by 2026 Amid Cancer and Antiviral Drug Advances - HPBL
AIM ImmunoTech Eyes a Resilient Comeback with Strategic Moves to Stay Afloat - Smartphone Magazine
AIM ImmunoTech gains NYSE compliance plan approval By Investing.com - Investing.com South Africa
Biotech Trailblazer AIM ImmunoTech Charts a Resilient Path to Equity Compliance - Jomfruland.net
AIM ImmunoTech gains NYSE compliance plan approval - Investing.com
AIM ImmunoTech Secures NYSE American Compliance Plan Approval – What It Means for Investors - HPBL
AIM ImmunoTech Says NYSE American Accepts Plan to Regain Compliance -February 26, 2025 at 01:37 pm EST - Marketscreener.com
AIM ImmunoTech Inc. Receives Approval from NYSE American for Compliance Plan with Listing Standards - Nasdaq
Can AIM ImmunoTech Maintain NYSE Listing? Exchange Grants Rare 2-Year Extension - StockTitan
AIM ImmunoTech Appoints David Chemerow to Board - TipRanks
AIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent Director - The Manila Times
Can This Former Comscore Executive Turn Around AIM ImmunoTech's Immuno-Pharma Ambitions? - StockTitan
AIM ImmunoTech Appoints David Chemerow To Board - citybiz
AIM Doses First New Subject in Phase 2 Study of Ampligen - GlobeNewswire
AIM ImmunoTech Doses First Subject in Phase 2 of Late-Stage Pancreatic Cancer Study - Marketscreener.com
Hemispherx Biopharma stock hits 52-week low at $0.12 By Investing.com - Investing.com South Africa
Hemispherx Biopharma stock hits 52-week low at $0.12 - Investing.com India
Finanzdaten der AIM ImmunoTech Inc-Aktie (AIM)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):